Repotrectinib yakagamuchira kukurumidza kubvumidzwa kubva kuUSFDA kune vakuru nevana varwere vane NTRK gene fusion-positive solid tumors.
June 2024: Chikafu neDrug Administration (FDA) yakapa kukurumidza kubvumidzwa kune repotrectinib (AUGTYRO, Bristol-Myers Squibb Kambani) yekurapa mabundu akasimba muvarwere vakuru nevana vane makore gumi nemaviri zvichikwira. Mamota aya anofanira kunge aine imwe genetic change inozivikanwa seneurotrophic tyrosine receptor kinase (NTRK) gene fusion, angave ari munharaunda kana kuti akapararira kune dzimwe nhengo dzemuviri, kana kuve nemukana wakakura wezvinetso zvakakomba zvinoitika kana kuvhiyiwa kwaitwa. Pamusoro pezvo, mabundu acho anofanira kunge aratidza kufambira mberi mushure mekurapwa kwekare kana kuti asina dzimwe nzira dzekurapa dzinoshanda dziripo.
Kubudirira kwekurapa kwakaongororwa mu a kliniki yekuedzwa inonzi TRIDENT-1 (NCT03093116). Muyedzo uyu waisanganisira varwere vechikuru makumi masere nevasere vane mabundu akasimba kana anopararira aive neiyo genetic mutation inonzi NTRK gene fusion. Varwere ava vakakamurwa kuita mapoka maviri: avo vaimbove yakagamuchira TRK tyrosine kinase inhibitor (TKI) (48 varwere) uye avo vakanga vasina kuwana TKI kare (40 varwere).
Pakutanga kwechidzidzo, varwere vese vakaongororwa kuti vaone chero kusagadzikana mune. central nerve system (CNS). Varwere vaive nehuropi metastases nekuonekwa zviratidzo hazvina kubatanidzwa muchidzidzo. Periodic ongororo dze tumarara yakaitwa panguva dze8-vhiki.
Yese mhinduro mwero (ORR) uye nguva yekupindura (DOR), zvichibva pane GADZIRA v1.1 maitiro, ndidzo nzira huru dzekuyera kuti chidzidzo chakashanda zvakanaka sei. Izvi zvakaongororwa nedare rekuongorora repakati rakanga risina kubatanidzwa nechidzidzo. Boka reTKI-naïve raive neORR yakasimbiswa ye58% (95% nguva yekuvimba [CI]: 41, 73), nepo boka reTKI-pretreated raive neORR yakasimbiswa ye50% (95% CI: 35, 65).
Nguva yepakati yekupindura (DOR) haigone kufungidzirwa (NE) (95% CI: NE, NE) muboka revarwere vakanga vasina kugamuchira TKI. mabatiro zvisati zvaitika, apo yaiva mwedzi 9.9 (95% CI: 7.4, 13.0) muboka revarwere vakanga vagamuchira kurapwa kweTKI kare.
Zvakanyanya (> 20%) divi zvinokonzerwa zvakataurwa zvaive dzungu, dysgeusia, peripheral neuropathy, kuvimbiswa, dyspnea, kuneta, ataxia, kukanganisa kwekuziva, kushaya simba kwetsandanyama, uye kusvotwa.
Iyo inokurudzirwa dosage ye repotrectinib iri 160 mg inotorwa nemuromo kamwe chete pazuva kwemazuva gumi nemana. Mushure mezvo, iyo dosi inofanira kuwedzerwa kusvika ku14 mg inotorwa kaviri pazuva, kana pasina kudya. Iyi regimen inofanirwa kuenderera mberi kusvika pane humbowo hwe chirwere kufambira mberi kana kuitika kwemigumisiro isingashiviriri.
Susan Hau muongorori akasarudzika mumunda wecancer cell therapy, aine tarisiro paT cell-based nzira uye vaccin yegomarara. Basa rake rinotora nzira dzinoverengeka dzekurapa, kusanganisira CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, uye NK (Natural Killer) cell therapy.
Hunyanzvi hwaHau huri mugomarara cell biology, kwaakaita zvakakosha kuti anzwisise kusangana kwakaoma pakati pemaseru edziviriro nemamota.
Tsvagiridzo yake ine chinangwa chekusimudzira kushanda kwe immunotherapies nekushandisa tumor microenvironment uye kuongorora nzira dzinoverengeka dzekumisikidza uye kutungamira mhinduro dzedziviriro kurwisa cancer maseru.
Muhupenyu hwake hwese, Hau akashanda pamwe nevanotungamira mapurofesa nevaongorori mumunda wekurapa cancer, muUnited States neChina.
Izvi zviitiko zvepasirese zvakawedzera maonero ake uye zvakabatsira pamaitiro ake matsva ekuvandudza kurapwa kwegomarara.
Basa raHau rinonyanya kutarisana nekugadzirisa matambudziko ekurapa epamusoro uye metastatic cancers. Akapinda muzviyedzo zvekiriniki achiongorora kuchengetedzeka uye kushanda kweakasiyana siyana immunotherapy nzira, kusanganisira inovimbisa Gamma Delta T cell therapy.
- Makomendi Akavharwa
- June 22nd, 2024
Durvalumab ine chemotherapy inotenderwa neUSFDA yekusawirirana kugadzirisa kushomeka kwekutanga kana kudzokororwa endometrial cancer.
Next Post:
Yakakurumidza kubvumidzwa 2023, Kenza yevakuru yakanangana nekurapa, NTRK gene fusion kurapwa, Pediatric solid bundu mishonga, Rare cancer precision mushonga, Repotrectinib FDA mvumo, TRK inhibitor kurapwa, Tropomyosin receptor kinase inhibitor